Showing results (71-80 of 382) with videos related to

Sort By:
Pageof 39
Journal of Immunology (Baltimore, Md. : 1950)|January 10, 2018
Inhibitors of the PD-1 Pathway in Tumor TherapyMartin W LaFleur, Yuki Muroyama, Charles G Drake, et al.
The Lancet. Oncology|October 5, 2015
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyAndrew B Sharabi, Michael Lim, Theodore L DeWeese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2015
New Strategies in Bladder Cancer: A Second Coming for ImmunotherapyAli Ghasemzadeh, Trinity J Bivalacqua, Noah M Hahn, et al.
Urology|July 6, 2015
Sickle Cell Disease in Priapism: Disparity in Care?Gregory A Joice, Max Kates, Nikolai A Sopko, et al.
The Journal of Urology|July 28, 2016
Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative SampleMeera R Chappidi, Max Kates, C J Stimson, et al.
American Journal of Respiratory and Critical Care Medicine|November 26, 2008
Validation of a model to predict perioperative mortality from lung cancer resection in the elderlyMax Kates, Xavier Perez, Julie Gribetz, et al.
The Journal of Urology|September 4, 2019
A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment ModelsMeera R Chappidi, C J Stimson, Max Kates, et al.
Urology|January 8, 2013
"Never events": Centers for Medicare and Medicaid Services complications after radical cystectomyGregory A Joice, Christopher M Deibert, Max Kates, et al.
BJU International|September 22, 2011
Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approachGina M Badalato, Max Kates, Juan P Wisnivesky, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a DifferenceDeborah R Kaye, Joseph K Canner, Max Kates, et al.
Pageof 39